Drugs Made in America Acquisition II swings to Q1 FY26 net income of $4.34 million

• Drugs Made in America Acquisition II posted net income of USD 4.34 million for the quarter ended March 31, 2026, swinging from a net loss of USD 59,327 a year earlier.
• Interest earned on cash and investments held in the trust account totaled USD 4.44 million, while general and administrative costs were USD 132,030.
• Cash on hand was USD 347,720 at March 31, 2026, up from USD 223 at Dec. 31, 2025.
• Management said substantial doubt exists about its ability to continue as a going concern within one year, tied to completing an initial business combination within its 24-month window.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-056651), on May 14, 2026, and is solely responsible for the information contained therein.